Aspirin COVID-19 studies. Benefit may be more likely without coadministered anticoagulants.
Recent:Drew Holt Reese Loucera Srinivasan Abul Malik.
Aspirin has been officially adopted
for early treatment in part of 1 country.
Submit updates/corrections .
Oct 4 |
(Preprint) (meta analysis) | Aspirin for COVID-19: real-time meta analysis of 54 studies |
| Statistically significant improvement is seen for mortality. 23 studies from 21 independent teams in 9 different countries show statistically significant improvements in isolation (18 for the most serious outcome). • Meta analysis using.. | ||
Aug 16 |
et al., medRxiv, doi:10.1101/2022.08.14.22278751 (Preprint) | Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk |
| 18% lower mortality [p=0.0004]. Retrospective 15,968 COVID-19 hospitalized patients in Spain, showing lower mortality with existing use of several medications including metformin, HCQ, aspirin, vitamin D, vitamin C, and budesonide. | ||
Aug 11 |
et al., American Heart Journal Plus: Cardiology Research and Practice, doi:10.1016/j.ahjo.2022.100191 (meta analysis) | Aspirin use is associated with decreased inpatient mortality in patients with COVID-19: A meta-analysis |
| 29% lower mortality [p=0.0003]. Meta analysis of 14 studies with 164,539 patients, showing lower mortality with aspirin. | ||
Aug 4 |
et al., medRxiv, doi:10.1101/2022.08.03.22278392 (Preprint) | Association of mortality and aspirin use for COVID-19 residents at VA Community Living Center Nursing Homes |
| 33% lower mortality [p=0.03] and 20% lower hospitalization [p=0.13]. Retrospective 1,687 nursing home residents in the USA, showing significantly lower risk of mortality with chronic low-dose aspirin use. Low dose 81mg aspirin users had treatment ≥10 of 14 days prior to the positive COVID date, control pat.. | ||
Jul 11 |
et al., Health Science Reports, doi:10.1002/hsr2.699 | Effect of low dose acetylsalicylic acid and anticoagulant on clinical outcomes in COVID‐19, analytical cross‐sectional study |
| 14% lower mortality [p=0.72], 28% lower ICU admission [p=0.17], 25% lower ARDS [p=0.39], and 2% lower hospitalization [p=0.94]. Retrospective 539 patients in the USA, showing lower mortality, ICU admission, and ARDS with aspirin treatment, without statistical significance. | ||
Jul 9 |
et al., BMC Infectious Diseases, doi:10.1186/s12879-022-07570-5 | Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial) |
| 22% lower mortality [p=0.62], 9% lower ventilation [p=0.8], and 30% lower progression [p=0.46]. RCT hospitalized patients in India, 224 treated with atorvastatin, 225 with aspirin, and 225 with both, showing lower serum interleukin-6 levels with aspirin, but no statistically significant changes in other outcomes. Low dose aspirin 75.. | ||
Jun 22 |
et al., Journal of the American Heart Association, doi:10.1161/JAHA.121.024530 | Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID‐19: A Propensity Score‐Matched Cohort Analysis of the HOPE‐COVID‐19 Registry |
| 38% lower mortality [p=0.02]. HOPE-COVID-19 PSM retrospective 7,824 patients, comparing prophylactic anticoagulation with and without additional treatment with aspirin in hospitalized patients, showing lower mortality with aspirin treatment. | ||
Jun 17 |
et al., Research and Practice in Thrombosis and Haemostasis, doi:10.1002/rth2.12743 | No association of low-dose aspirin with severe COVID-19 in France: A cohort of 31.1 million people without cardiovascular disease |
| 4% higher combined mortality/intubation [p=0.18] and 3% higher hospitalization [p=0.05]. Retrospective 31 million people without cardiovascular disease in France, showing no significant difference in hospitalization or combined intubation/death with low dose aspirin prophylaxis. | ||
May 30 |
et al., Cureus, doi:10.7759/cureus.25467 | Efficacy and Safety of Aspirin, Promethazine, and Micronutrients for Rapid Clinical Recovery in Mild to Moderate COVID-19 Patients: A Randomized Controlled Clinical Trial |
| 89% improved recovery [p=0.05]. RCT 260 patients in India, 130 treated with aspirin, promethazine, vitamin C, D, B3, zinc, and selenium, showing faster recovery with treatment. There was no hospitalization, ICU admission, or supplemental oxygen requirements in either gr.. | ||
May 5 |
et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2022.07.017 (date from earlier preprint) | Pre-hospital aspirin use and patient outcomes in COVID-19: Results from the International Viral Infection and Respiratory Illness Universal Study (VIRUS) |
| 11% lower mortality [p=0.01], 22% lower ICU admission [p<0.0001], and 9% lower progression [p=0.02]. Retrospective 21,579 hospitalized COVID-19 patients mostly in the USA, showing lower risk of mortality and severity with existing aspirin use. | ||
May 5 |
et al., PLOS ONE, doi:10.1371/journal.pone.0267462 | Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen and relationship with mortality among United States Veterans after testing positive for COVID-19 |
| 3% lower mortality [p=0.06]. Retrospective 28,856 COVID-19 patients in the USA, showing no significant difference in mortality for chronic aspirin use vs. sporadic NSAID use. Since aspirin is available OTC and authors only tracked prescriptions, many patients classif.. | ||
May 2 |
et al., medRxiv, doi:10.1101/2021.04.28.21256261 (Preprint) | Aspirin and NSAID use and the risk of COVID-19 |
| 22% lower progression [p=0.3] and 3% more cases [p=0.8]. Retrospective 2,736,091 individuals in the U.S., U.K., and Sweden, showing lower risk of hospital/clinic visits with aspirin use. | ||
Mar 24 |
et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2022.3890 | Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19 |
| 13% lower mortality [p<0.0001]. Retrospective 112,269 hospitalized COVID-19 patients in the USA, showing lower mortality with aspirin treatment. | ||
Mar 22 |
et al., JAMA, doi:10.1001/jama.2022.2910 | Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial |
| 16% lower mortality [p=0.05], 17% higher hospital discharge [p=0.08], and 21% lower progression [p=0.02]. RCT 1,557 critical patients, showing significantly lower mortality with aspirin, with 97.5% posterior probability of efficacy. | ||
Mar 9 |
et al., World Journal of Critical Care Medicine, doi:10.5492/wjccm.v11.i2.92 | Retrospective analysis of aspirin's role in the severity of COVID-19 pneumonia |
| 6% higher mortality [p=0.87], 50% lower ventilation [p=0.16], and 49% lower ICU admission [p=0.41]. Retrospective 125 COVID+ hospitalized patients in the USA, showing no significant differences with aspirin prophylaxis. | ||
Feb 28 |
et al., Bosnian Journal of Basic Medical Sciences, doi:10.17305/bjbms.2021.7009 | The impact of vitamin and mineral supplements usage prior to COVID-19 infection on disease severity and hospitalization |
| 4% lower hospitalization [p=0.08] and 18% higher severe cases [p=0.28]. Retrospective survey based analysis of 2,148 COVID-19 recovered patients in Jordan, showing no significant differences in the risk of severity and hospitalization with aspirin prophylaxis. | ||
Jan 31 |
et al., Gerontology, doi:10.1159/000521412 | Frail Older Adults with Presymptomatic SARS-CoV-2 Infection: Clinical Course and Prognosis |
| 26% lower combined mortality/hospitalization [p=0.13]. Retrospective 849 COVID-19+ patients in skilled nursing homes, showing lower risk of combined hospitalization/death with aspirin prophylaxis, not reaching statistical significance. | ||
Jan 24 |
et al., Archives of Medical Research, doi:10.1016/j.arcmed.2022.01.002 | A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19 |
| 59% lower combined mortality/hospitalization [p<0.0001], 15% lower mortality [p=0.16], 9% lower ventilation [p=0.51], and 48% lower hospitalization [p<0.0001]. Retrospective 28,048 COVID+ patients in Mexico, 7,898 receiving a treatment kit including low dose ivermectin, AZ, aspirin, and acetaminophen, shower lower mortality/hospitalization for those receiving the kit. Delivery of the treatment k.. | ||
Jan 8 |
et al., Pharmaceuticals, doi:10.3390/ph15010078 | A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis |
| 31% higher mortality [p=0.04]. PSM retrospective 3,712 hospitalized patients in Spain, showing lower mortality with existing use of azithromycin, bemiparine, budesonide-formoterol fumarate, cefuroxime, colchicine, enoxaparin, ipratropium bromide, loratadine, mepyramine.. | ||
Jan 7 |
et al., GeroScience, doi:10.1007/s11357-021-00499-8 | Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS-CoV-2 pneumonia |
| 10% higher mortality [p=0.52], 110% higher ICU admission [p=0.007], and 10% longer hospitalization [p=0.02]. Retrospective 1,047 pneumonia patients in 5 COVID-19 geriatric units in France and Switzerland, significantly higher ICU admission and longer hospital stays with existing aspirin treatment. Numbers in this study appear to be inconsistent,.. | ||
Dec 29 2021 |
et al., Exploratory Research in Clinical and Social Pharmacy, doi:10.1016/j.rcsop.2021.100101 | Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan |
| 44% lower mortality [p=0.28]. Retrospective 444 hospitalized patients in Pakistan, showing lower mortality with aspirin treatment in unadjusted results, not reaching statistical significance. | ||
Dec 24 2021 |
et al., International Journal of Medicine in Developing Countries, doi:10.24911/IJMDC.51-1640383699 (meta analysis) | A systematic review and meta-analysis on efficacy of low dose aspirin on the management of COVID-19 |
| 49% lower mortality [p<0.0001] and 30% lower ventilation [p=0.006]. Meta analysis of 8 studies showing significantly lower mortality and mechanical ventilation with low dose aspirin. | ||
Nov 18 2021 |
Collaborative Group, The Lancet, doi:10.1016/S0140-6736(21)01825-0 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |
| 4% lower mortality [p=0.35], 5% lower ventilation [p=0.32], 6% higher hospital discharge [p=0.006], and 11% shorter hospitalization. RCT 14,892 late stage patients, 7,351 treated with aspirin, showing slightly improved discharge and hospitalization time, and no significant difference for mortality. Results are limited due to low dose (150mg daily), very late treatment .. | ||
Oct 14 2021 |
et al., European Heart Journal, doi:10.1093/eurheartj/ehab724.3002 | Antiplatelet therapy and outcome in patients with COVID-19. Results from a multi-center international prospective registry (HOPE-COVID19) |
| 71% lower mortality [p<0.0001]. Retrospective database analysis of 7,824 patients in the HOPE-COVID19 registry, 730 receiving antiplatelet therapy including aspirin, showing lower mortality with treatment. Authors do not provide results restricted to aspirin. | ||
Oct 11 2021 |
et al., JAMA, doi:10.1001/jama.2021.1727283 | Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19 |
| 67% lower hospitalization [p=0.49] and 19% lower progression [p=0.78]. Early terminated RCT with 164 aspirin and 164 control patients in the USA with very few events, showing no significant difference with aspirin treatment for the combined endpoint of all-cause mortality, symptomatic venous or arterial thro.. | ||
Oct 4 2021 |
et al., Medicina Clínica, doi:10.1016/j.medcle.2021.02.010 | Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data |
| 49% higher mortality [p=0.0001]. Retrospective 770 COVID-19 patients with cancer, showing increased mortality with aspirin use in unadjusted results. | ||
Oct 4 2021 |
et al., International Journal of Cardiology, doi:10.1016/j.ijcard.2021.09.058 | Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study |
| 7% higher mortality [p=0.65] and 30% lower combined mortality/intubation [p=0.01]. Retrospective 984 COVID-19 patients, 253 taking aspirin prior to admission, showing lower risk of respiratory support upgrade with treatment. | ||
Oct 2 2021 |
et al., Metabolites, doi:10.3390/metabo11100679 | Clinical Predictors of Mortality and Critical Illness in Patients with COVID-19 Pneumonia |
| 13% higher mortality [p=0.0003]. Retrospective 390 hospitalized patients in Israel, showing higher risk of mortality with prior aspirin use. Details of the analysis are not provided. | ||
Oct 1 2021 |
et al., Anesthesiology, doi:10.1097/ALN.0000000000003999 | Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study |
| 43% lower mortality [p=0.0006]. Retrospective 2,070 hospitalized patients in the USA, showing lower mortality with aspirin treatment. | ||
Sep 4 2021 |
et al., Medicina, doi:10.3390/medicina57090931 | Aspirin Is Related to Worse Clinical Outcomes of COVID-19 |
| 700% higher mortality [p=0.03], 433% higher ventilation [p=0.14], 433% higher ICU admission [p=0.14], and 33% fewer cases [p=0.29]. Retrospective database analysis of 22,660 patients tested for COVID-19 in South Korea. There was no significant difference in cases according to aspirin use. Aspirin use before COVID-19 was related to an increased death rate and aspirin u.. | ||
Sep 3 2021 |
et al., Journal of Intensive Care Medicine, doi:10.1177/08850666221093229 | Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study |
| 27% lower mortality [p=0.03]. Retrospective 1,033 critical condition patients, showing lower in-hospital mortality with aspirin in PSM analysis. Patients receiving aspirin also had a higher risk of significant bleeding, although not reaching statistical significance. .. | ||
Sep 1 2021 |
et al., Microbial Drug Resistance, doi:10.1089/mdr.2020.0489 | Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single Center Experience |
| 46% lower mortality [p=0.63]. Retrospective 32 ICU patients showing lower mortality with aspirin treatment, without statistical significance. | ||
Aug 29 2021 |
et al., Journal of Thrombosis and Haemostasis, doi:10.1111/jth.15517 | Association of Pre-Hospital Antiplatelet Therapy with Survival in Patients Hospitalized with COVID-19: A Propensity Score-Matched Analysis |
| 19% lower mortality [p=0.005] and 3% lower ventilation [p=0.21]. PSM retrospective 6,781 hospitalized patients ≥50 years old in the USA who were on pre-hospital antiplatelet therapy (84% aspirin), and 10,566 matched controls, showing lower mortality with treatment. | ||
Aug 18 2021 |
et al., Drugs & Aging, doi:10.1007/s40266-021-00886-y | Sex Differences in Association Between Anti-Hypertensive Medications and Risk of COVID-19 in Middle-Aged and Older Adults |
| 9% lower mortality [p=0.12], 2% lower hospitalization [p=0.47], 9% more symptomatic cases [p=0.18], and 7% more cases [p=0.09]. UK Biobank retrospective 77,271 patients aged 50-86, showing no significant differences with aspirin use. Matching lead to different results for the gender vs. overall analysis, for example the overall result for cases was OR 1.07, howeve.. | ||
Jul 30 2021 |
et al., Medicine, doi:10.1097/MD.0000000000026670 | Effect of aspirin on coronavirus disease 2019 |
| 24% lower mortality [p=0.52], 7% higher progression [p=0.8], and 11% more cases [p=0.21]. PSM retrospective case control study in South Korea, showing a trend towards lower mortality, but no significant differences with aspirin use. | ||
Jul 30 2021 |
et al., Clinical Drug Investigation, doi:10.1007/s40261-021-01061-2 | Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study |
| 8% higher ventilation [p=0.93]. Retrospective 225 hospitalized patients in Egypt, showing significantly lower thromboembolic events with aspirin treatment, but no significant difference in the need for mechanical ventilation. | ||
Jul 20 2021 |
et al., Identification of Biomarkers, New Treatments, and Vaccines for COVID-19, doi:10.1007/978-3-030-71697-4_17 | Association of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19 |
| 22% lower mortality [p=0.56] and 10% higher ICU admission [p=0.67]. Retrospective 587 COVID+ hospitalized patients in Iran, showing no significant differences in outcomes with aspirin treatment. | ||
Jun 30 2021 |
et al., Journal of Infection, doi:10.1016/j.jinf.2021.02.008 | Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study |
| 96% lower progression [p=0.0005]. Observational study in France with 28 hospitalized patients treated with prednisone/furosemide/colchicine/salicylate/direct anti-Xa inhibitor, and 40 control patients, showing lower combined mortality, ventilation, or high-flow oxygen the.. | ||
Jun 17 2021 |
et al., Yonsei Medical Journal, doi:10.3349/ymj.2021.62.7.577 | Incidence and Mortality Associated with Cardiovascular Medication among Hypertensive COVID-19 Patients in South Korea |
| 1% lower mortality [p=0.95] and 12% fewer cases [p=0.04]. Retrospective database analysis of 328,374 adults in South Korea, showing lower risk of COVID-19 cases with aspirin use, but no difference in mortality for COVID-19 patients. | ||
May 26 2021 |
et al., Research Square, doi:10.21203/rs.3.rs-365321/v2 (Preprint) | Case Characteristics, Clinical Data, And Outcomes of Hospitalized COVID-19 Patients In Qom Province, Iran: A Prospective Cohort Study |
| 32% higher mortality [p=0.04]. Prospective study of 2,468 hospitalized COVID-19 patients in Iran, showing higher mortality with aspirin treatment. IR.MUQ.REC.1399.013. | ||
May 26 2021 |
et al., Heart & Lung, doi:10.1016/j.hrtlng.2021.04.010 | Pre-hospital antiplatelet medication use on COVID-19 disease severity |
| 13% higher mortality [p=0.63] and 2% higher combined mortality/intubation [p=0.93]. Retrospective 762 COVID+ hospitalized patients in the USA, 239 on antiplatelet medication (199 aspirin), showing no significant differences in outcomes. For more discussion see . | ||
May 19 2021 |
et al., Vascular Medicine, doi:10.1177/1358863X211012754 | Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19 |
| 13% lower mortality [p=0.53]. PSM retrospective 1,994 PCR+ patients in the USA, not showing a significant difference in mortality with aspirin treatment. | ||
Apr 30 2021 |
et al., PLOS ONE, doi:10.1371/journal.pone.0251085 | Epidemiology, outcomes, and utilization of intensive care unit resources for critically ill COVID-19 patients in Libya: A prospective multi-center cohort study |
| 10% lower mortality [p=0.5]. Prospective study of 465 COVID-19 ICU patients in Libya showing no significant differences with treatment. | ||
Apr 29 2021 |
et al., Journal of Medical Virology, doi:10.1002/jmv.27053 | Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19 |
| 25% lower mortality [p=0.04]. Retrospective 991 hospitalized patients in Iran, showing lower mortality with aspirin treatment. | ||
Apr 20 2021 |
et al., medRxiv, doi:10.1101/2021.04.13.21255438 (Preprint) | Cyclooxygenase inhibitor use is associated with increased COVID-19 severity |
| 61% higher mortality [p<0.0001] and 309% higher severe cases [p<0.0001]. N3C retrospective 250,533 patients showing significantly higher mortality with aspirin use. Note that aspirin results were not included in the journal version or v2 of this preprint. | ||
Apr 7 2021 |
et al., BMJ Open, doi:10.1136/bmjopen-2020-042042 | 3219 hospitalised patients with COVID-19 in Southeast Michigan: a retrospective case cohort study |
| 14% higher mortality [p=0.21]. Retrospective database analysis of 3,219 hospitalized patients in the USA. Very different results in the time period analysis (Table S2), and results significantly different to other studies for the same medications (e.g., heparin OR 3.06.. | ||
Apr 1 2021 |
et al., Anesthesia & Analgesia, doi:10.1213/ANE.0000000000005292 | Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019 |
| 47% lower mortality [p=0.02], 44% lower ventilation [p=0.007], and 43% lower ICU admission [p=0.007]. Retrospective 412 hospitalized patients, 98 treated with aspirin, showing lower mortality, ventilation, and ICU admission with treatment. | ||
Mar 31 2021 |
et al., Signal Transduction and Targeted Therapy, doi:10.1038/s41392-021-00689-y (date from earlier preprint) | Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients |
| 15% lower mortality [p=0.08]. PSM retrospective TriNetX database analysis of 1,379 severe COVID-19 patients requiring respiratory support, showing lower mortality with aspirin (not reaching statistical significance) and famotidine, and improved results from the combin.. | ||
Feb 23 2021 |
et al., The FEBS Journal, doi:10.1111/febs.15784 | The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection |
| 28% fewer cases [p=0.04] and 10% faster viral clearance [p=0.05]. Retrospective 10,477 patients in Israel, showing lower risk of COVID-19 cases with existing aspiring use. | ||
Feb 12 2021 |
et al., Medicine, doi:10.1097/MD.0000000000024544 | Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19 |
| 75% lower mortality [p=0.03] and 2% slower viral clearance [p=0.94]. Retrospective PSM analysis of 232 hospitalized patients, 28 treated with aspirin, showing lower mortality with treatment. There was no significant difference in viral clearance. | ||
Feb 11 2021 |
et al., PloS ONE, doi:10.1371/journal.pone.0246825 | Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration |
| 59% lower mortality [p<0.0001]. Retrospective PSM analysis of pre-existing aspirin use in the USA, showing lower mortality with treatment. | ||
Jan 21 2021 |
et al., American Journal of Hematology, doi:10.1002/ajh.26102 | Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis |
| 48% lower mortality [p=0.004]. Retrospective 638 matched hospitalized patients in the USA, 319 treated with aspirin, showing lower mortality with treatment. | ||
Dec 18 2020 |
et al., Journal of Cellular and Molecular Medicine, doi:10.1111/jcmm.16198 | Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease |
| 4% lower mortality [p=0.89]. Retrospective 183 hospitalized patients in China, 52 taking low-dose aspirin prior to hospitalization, showing no significant difference with treatment. | ||
Nov 29 2020 |
et al., Internal and Emergency Medicine, doi:10.1007/s11739-021-02870-1 | Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry |
| 3% higher mortality [p=0.48], 3% higher ventilation [p=0.75], and 4% higher ICU admission [p=0.65]. Retrospective 20,641 hospitalized patients in Spain, showing no significant difference in outcomes with existing aspirin use. | ||
Nov 5 2020 |
et al., Blood, doi:10.1182/blood-2020-143349 | Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis |
| 35% lower mortality [p=0.04], 49% higher ventilation [p=0.04], and 45% higher ICU admission [p=0.02]. PSM retrospective 2,785 hospitalized patients in the USA, showing lower mortality and higher ventilation and ICU admission with aspirin treatment. | ||
Oct 31 2020 |
et al., ResearchGate, doi:10.13140/RG.2.2.26038.93762/2 (Preprint) | Beneficial effect of low dose aspirin (Acetyl salicylic acid) in adult Covid-19 patients: a retrospective observational study in Bangladesh |
| 96% lower progression [p=0.001]. Retrospective 42 patients in Bangladesh, 11 treated with aspirin, showing fewer complications with treatment. | ||
Sep 9 2020 |
et al., Tohoku J. Exp. Med., 2020, 252, 73-84, doi:10.1620/tjem.252.73 | Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran |
| 28% higher mortality [p=0.52]. Retrospective 459 patients in Iran, 53 treated with aspirin, showing no significant difference with treatment. | ||
Jul 14 2020 |
et al., Journal of Hematology & Oncology, doi:10.1186/s13045-020-00934-x | A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward |
| 58% lower mortality [p=0.43]. Retrospective 58 multiple myeloma COVID-19 patients in the USA, showing no significant difference with aspirin treatment. | ||
May 7 2020 |
et al., Journal of Hypertension, doi:10.1097/hjh.0000000000002515 | Influence of inhibitors of the renin–angiotensin system on risk of acute respiratory distress syndrome in Danish hospitalized COVID-19 patients |
| 34% higher combined mortality/ICU admission [p=0.09]. Retrospective 689 hospitalized COVID-19 patients in Denmark, showing higher risk of ICU/death with aspirin use in unadjusted results subject to confounding by indication. | ||
May 4 2020 |
et al., medRxiv, doi:10.1101/2020.05.04.20089904 (Preprint) | Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea |
| 71% fewer cases [p=0.001]. Retrospective database analysis of 65,149 in South Korea, showing significantly lower cases with existing aspirin treatment. The journal version of this paper does not present the aspirin results (only combined results for NSAIDs). | ||
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.